Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom

M. F. Botteman J. W. Hay; M. P. Luo; A. S. Curry; R. L. Wong; and B. A. van Hout

首页> 外文期刊>Rheumatology >Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom

【24h】

Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom

机译：阿达木单抗在英国治疗强直性脊柱炎的成本效益

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objectives. This study evaluated the cost effectiveness of adalimumab vs conventional therapy in patients with active ankylosing spondylitis (AS).

机译：目标。这项研究评估了阿达木单抗与传统疗法在活动性强直性脊柱炎（AS）患者中的成本效益。

著录项

来源
《Rheumatology》 |2007年第8期|1320-1328|共9页
作者
M. F. Botteman J. W. Hay; M. P. Luo; A. S. Curry; R. L. Wong; and B. A. van Hout;
展开▼
作者单位

Pharmerit North America LLC Bethesda MD;

University of Southern California Los Angeles CA;

Abbott Laboratories Abbott Park IL USA;

Abbott Laboratories Berks UK;

Abbott Laboratories Parsippany NJ USA and;

University Medical Centre Utrecht Utrecht The Netherlands.;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom. [J] . Botteman MF, Hay JW, Luo MP, Rheumatology . 2007,第8期

机译：阿达木单抗在英国治疗强直性脊柱炎的成本效益。
2. Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance [J] . G. Kobelt Rheumatology . 2008,第10期

机译：评论：英夫利昔单抗，依那西普和阿达木单抗用于治疗强直性脊柱炎：成本效益证据和NICE指南
3. Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: Editor's note [J] . Rheumatology . 2008,第10期

机译：评论：英夫利昔单抗，依那西普和阿达木单抗用于治疗强直性脊柱炎：成本效益证据和NICE指南：编者按
4. Legal Aspects of End of Life Treatment in Australia, Canada, the United States, the United Kingdom, Poland, France, Germany, Japan, and The Netherlands [C] . Danuta Mendelson, Timothy Stoltzfus Jost, Michael Ashby World Congress on Pain . 2003

机译：澳大利亚，加拿大，美国，英国，波兰，法国，德国，日本和荷兰生命治疗结束的法律方面
5. Exercise Partially Explains the Impact of Body Mass Index on Disease Activity in Ankylosing Spondylitis [D] . ?Liew, Jean W. 2020

机译：运动也部分解释了身体质量指数对疾病活动强直性脊柱炎的影响
6. Extended report: Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial [O] . D van der Heijde, M H Schiff, J Sieper, -1

机译：扩展报告：阿达木单抗在治疗强直性脊柱炎中的功效可维持长达2年：ATLAS试验的长期结果
7. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom [O] . M. F. Botteman, J. W. Hay, M. P. Luo, 2007

机译：阿巴木单抗的成本效益治疗英国强直性脊柱炎

Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom

摘要

著录项

相似文献

相关主题

期刊订阅